All In Biotech

BLA 103909 · Genentech

Tnkase

Tenecteplase

Novel

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jun 2, 2000

Approved uses

2

Original approval plus efficacy supplements

Registered trials

142

88 Phase 3, 49 recruiting

FAERS reports

1,600

1,196 serious, 375 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2025.

TNKase ® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). TNKase is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). ( 1 )

Mechanism: Tenecteplase is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin. In the presence of fibrin, in vitro studies demonstrate that tenecteplase-mediated conversion of plasminogen to plasmin is increased relative to its conversion in the absence of fibrin. This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen as compared to a molecule lacking this property. The clinical significance of fibrin-specificity on safety (e.g., bleeding) or efficacy has not been...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TNKASE · TENECTEPLASE 50MG/VIAL · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tenecteplase" as an intervention, any sponsor and status, largest first.

All 142 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use412
  • no adverse event316
  • cerebral haemorrhage162
  • angioedema129
  • haemorrhage intracranial118
  • death81
  • haemorrhage81
  • drug ineffective72
  • cerebrovascular accident71
  • haemorrhagic transformation stroke61
  • subarachnoid haemorrhage47
  • medication error40

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200425
200531
200612
200725
200815
200937
201014
201132
201255
201356
201428
201518
201616
201778
201848
201944
202055
202174
2022101
2023168
2024345
2025177
2026146

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Tnkase (Tenecteplase) · HCPCS J3101

2024 spending

$30.5M

Beneficiaries

4,258

4,266 claims

Per beneficiary

$7,153

2024 ASP limit $155.35 per unit

View as table
YearSpending
2020$5,793,904
2021$7,358,267
2022$13,250,569
2023$23,404,561
2024$30,455,382

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 306 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.